NASDAQ:IDXGInterpace Diagnostics Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Interpace Diagnostics Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.66 -0.01 (-0.21 %) (As of 07/14/2020 03:32 PM ET) Add Compare Share Today's Range$4.51Now: $4.66▼$4.6950-Day Range$4.41MA: $5.24▼$6.1452-Week Range$3.81Now: $4.66▼$11.00Volume4,145 shsAverage Volume536,470 shsMarket Capitalization$18.83 millionP/E RatioN/ADividend YieldN/ABeta1.69 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingInterpace Diagnostics Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.81, Interpace Diagnostics Group has a potential upside of 89.1% from its current price of $4.66.Amount of Analyst CoverageInterpace Diagnostics Group has only been the subject of 4 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesInterpace Diagnostics Group has received 305 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInterpace Diagnostics Group has received 213 “underperform” votes. (Add your “underperform” vote.)Community SentimentInterpace Diagnostics Group has received 58.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote “Outperform” if you believe IDXG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInterpace Diagnostics Group does not currently pay a dividend.Dividend GrowthInterpace Diagnostics Group does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Interpace Diagnostics Group insiders have not sold or bought any company stock.Percentage Held by Insiders54.40% of the stock of Interpace Diagnostics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 18.83% of the stock of Interpace Diagnostics Group is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Interpace Diagnostics Group are expected to grow in the coming year, from ($5.30) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Interpace Diagnostics Group is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Interpace Diagnostics Group is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInterpace Diagnostics Group has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:IDXG Previous Symbol CUSIP69329V10 CIK1054102 Webwww.interpace.com Phone855-776-6419Debt Debt-to-Equity Ratio0.38 Current Ratio1.79 Quick Ratio1.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$24.08 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.41 per share Price / Book1.37Profitability EPS (Most Recent Fiscal Year)($5.58) Net Income$-26,730,000.00 Net Margins-110.80% Return on Equity-145.12% Return on Assets-39.55%Miscellaneous Employees176 Outstanding Shares4,040,000Market Cap$18.83 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:IDXG Rates by TradingView Receive IDXG News and Ratings via Email Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions How has Interpace Diagnostics Group's stock been impacted by COVID-19 (Coronavirus)? Interpace Diagnostics Group's stock was trading at $6.46 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IDXG stock has decreased by 27.9% and is now trading at $4.66. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Interpace Diagnostics Group? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Interpace Diagnostics Group. When is Interpace Diagnostics Group's next earnings date? Interpace Diagnostics Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Interpace Diagnostics Group. How were Interpace Diagnostics Group's earnings last quarter? Interpace Diagnostics Group Inc (NASDAQ:IDXG) issued its earnings results on Thursday, June, 25th. The business services provider reported ($2.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.24) by $1.08. The business services provider had revenue of $9.20 million for the quarter, compared to the consensus estimate of $8.95 million. Interpace Diagnostics Group had a negative net margin of 110.80% and a negative return on equity of 145.12%. View Interpace Diagnostics Group's earnings history. What guidance has Interpace Diagnostics Group issued on next quarter's earnings? Interpace Diagnostics Group issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, June, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.6-6 million, compared to the consensus revenue estimate of $6.27 million. What price target have analysts set for IDXG? 5 equities research analysts have issued 12-month price objectives for Interpace Diagnostics Group's stock. Their forecasts range from $3.00 to $12.00. On average, they anticipate Interpace Diagnostics Group's share price to reach $8.81 in the next year. This suggests a possible upside of 89.1% from the stock's current price. View analysts' price targets for Interpace Diagnostics Group. Has Interpace Diagnostics Group been receiving favorable news coverage? News headlines about IDXG stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news articles about the business services provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Interpace Diagnostics Group. Are investors shorting Interpace Diagnostics Group? Interpace Diagnostics Group saw a decline in short interest in June. As of June 15th, there was short interest totaling 99,100 shares, a decline of 18.6% from the May 31st total of 121,700 shares. Based on an average trading volume of 80,900 shares, the short-interest ratio is presently 1.2 days. Approximately 2.5% of the shares of the company are short sold. View Interpace Diagnostics Group's Current Options Chain. Who are some of Interpace Diagnostics Group's key competitors? Some companies that are related to Interpace Diagnostics Group include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY) and Cross Country Healthcare (CCRN). View all competitors. What other stocks do shareholders of Interpace Diagnostics Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), AT&T (T), Trevena (TRVN), Genocea Biosciences (GNCA) and AbbVie (ABBV). Who are Interpace Diagnostics Group's key executives? Interpace Diagnostics Group's management team includes the following people: Mr. Jack E. Stover, CEO, Pres & Director (Age 67, Pay $621.68k)Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 53, Pay $424.24k)Mr. Fred S. Knechtel, CFO, Treasurer & Company Sec. (Age 59)Mr. Glenn Gershon, Sr. VP of OperationsMr. Thomas John Freeburg, Chief Accounting Officer (Age 52) What is Interpace Diagnostics Group's stock symbol? Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG." How do I buy shares of Interpace Diagnostics Group? Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Interpace Diagnostics Group's stock price today? One share of IDXG stock can currently be purchased for approximately $4.66. How big of a company is Interpace Diagnostics Group? Interpace Diagnostics Group has a market capitalization of $18.83 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. Interpace Diagnostics Group employs 176 workers across the globe. What is Interpace Diagnostics Group's official website? The official website for Interpace Diagnostics Group is www.interpace.com. How can I contact Interpace Diagnostics Group? Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
